Latest Morning Briefing Stories
Five Quick Ways HHS Secretary Tom Price Could Change The Course Of Health Policy
After a tough fight by Democrats, Senate Republicans confirmed Rep. Tom Price’s nomination to head the Department of Health and Human Services. He will have the authority to upend some current practices.
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
‘Massive Confusion’ Abounds For Insurers As GOP Wavers On Obamacare Redo
Republicans’ delay in finding common ground to repeal and replace the health law raises risks that coverage could shrink and rates rise even more, the industry says.
Nuevas drogas contra el cáncer, ¿ayudan a vivir más?
Empujados por defensores de pacientes que quieren acceso temprano a los medicamentos, la FDA ha aprobado una ráfaga de drogas oncológicas en los últimos años, Pero pocas de estas drogas han permitido a pacientes con una esperanza de vida limitada, vivir por años.
Georgia Legislative Panel Hears Concerns About Surprise Medical Billing
Insurers and care providers say efforts to fix how consumers are notified also raise concerns.
With A High Deductible, Even A Doctor Can Shortchange His Health
A Harvard health policy expert faced a racing heartbeat and $6,000 deductible on his insurance plan. What did he do?
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
HSAs: ‘Tax-Break Trifecta’ Or Insurance Gimmick Benefiting The Wealthy?
Republicans hope to expand the use of health savings accounts to encourage consumers to be more judicious in using their coverage. Here’s an explainer of how they work.
Hospitals Worry Repeal Of Obamacare Would Jeopardize Innovations In Care
One part of the federal health law gave hospitals financial incentives to improve patient care. Some invested big to make those changes and are worried about what losing that support would mean.
Renewed Cleaning Efforts For Scopes Not Enough To Vanquish Bacteria
A new study, though small, finds extensive damage to commonly used medical scopes that could trap dangerous bacteria. That raises concerns about the potential for more outbreaks.
Everything You Need To Know About Block Grants — The Heart Of GOP’s Medicaid Plans
Republican plans to transform Medicaid could help set debate on the role of government and entitlements. Here’s an explanation of how it could work.
People With Medical Debt Most Likely To Be Dunned By Collection Agencies
The Consumer Financial Protection Bureau reports in a new study that 59 percent of people contacted by a debt collector had outstanding medical bills.
California’s Community Clinics, Big ACA Beneficiaries, Worry About Their Future
A flow of Medi-Cal expansion dollars — and patients — has fueled significant growth, making clinics in California one of the linchpins of primary care under Obamacare.
Sleeping Like A Baby Is A $325 Million Industry
Newborn sleep is a valuable commodity.
KHN Video: Orphan Drugs Creating Gold Rush For Pharmaceutical Firms
The designation, which is made by the Food and Drug Administration, allows drugmakers to claim seven years of market exclusivity.
Inside Hospital, Families Find Refuge With Recliners, Tissues And Cake
More hospitals, including Montefiore Medical Center in New York, are setting up support centers to help stressed-out family members cope.
Sin Obamacare, ¿qué pasará con el seguro de salud a través de su empleo?
Si piensas que porque tienes seguro de salud a través de tu trabajo en una gran compañía, no te afectará si los republicanos cambian el Obamacare, piénsalo dos veces. Muchas de las provisiones de la ley también aplican a los planes ofrecidos por grandes empleadores.
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Una investigación de Kaiser Health News analiza las acciones de compañias farmacéuticas para manipular los precios de medicamentos huérfanos, utilizados para tratar enfermedades raras.
Large Employer Health Plans Could Also See Some Impacts From Obamacare Overhaul
With the future of Obamacare on the line, workers might want to consider what benefits they have gained through the landmark law.
